AI Therapeutics
2013
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Series C
LATEST DEAL TYPE
$58M
LATEST DEAL AMOUNT
3
INVESTORS
Description
Developer of precision therapeutics technology designed to outsmart cancer and rare diseases. The company's technology accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics and combinational drug screening with deep learning to match clinical drugs, enabling doctors to treat Lymphangioleiomyomatosis by providing significant therapeutic benefit for patients.
Website
Formerly Known As
LAM Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 530 Old Whitfield Street
- Guilford, CT 06437
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore AI Therapeutics’s full profile, request a free trial.
AI Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 30-Mar-2017 | $58M | 0000 | 00000 | Completed | Startup |
| 3. Corporate (Series B) | 03-Feb-2016 | 0000 | 0000 | 0000 | Completed | Startup |
| 2. Early Stage VC (Series A) | 06-Jun-2013 | $20M | $20M | 0000 | Completed | Startup |
| 1. Accelerator/Incubator | Completed | Startup |
AI Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 00,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series A | 25,250,000 | $0.000100 | 8% | $0.8 | $0.8 | 1x | $0.8 | 30.53% |
AI Therapeutics Competitors (37)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immatics | Venture Capital-Backed | Tübingen, Germany | 000 | 00000 | 00000000000 | 00000 |
| 00000000 | Formerly VC-backed | Munich, Germany | 000.00 | 000000&0 | 000.00 | |
| 000000 00000000000 | Failed Transaction (M&A) | Cambridge, MA | 000 | 00000 | 000000&0 | |
| 0000000 0000000000 | Formerly VC-backed | Richmond, CA | 000 | 000.00 | 00000000 | 000.00 |
| 0000000000 | Venture Capital-Backed | Abingdon, United Kingdom | 000 | 00000 | 00000000000 | 00000 |
AI Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Yonghua Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Xiphos Bio | Corporation | Minority | 000 0000 | 000000 0 | ||
| 4Catalyzer | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |
AI Therapeutics Executive Team (4)
AI Therapeutics Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| George Rehm JD | Self | Board Member | 000 0000 | |
| Gregg Fergus | 4Catalyzer | Board Member | 000 0000 | |
| Jonathan Rothberg Ph.D | Self | Co-Founder & Board Member | 000 0000 |